Skip to main content
Supplement Research and Comparison WebsiteBest Price GuaranteeAbout Us
Supplement Research and Comparison Website

Abstract

Objectives: The larger number of bifidobacteria in the intestine of breast-fed infants has been associated with their better health compared with formula-fed infants. We assessed the safety and tolerability of an experimental formula containing 2 x 10(7) colony-forming units of Bifidobacterium longum BL999 and 4 g/L of a prebiotic mixture containing 90% galacto-oligosaccharides and 10% fructo-oligosaccharides.

Methods: A 7-mo prospective, randomized, reference-controlled, double-blinded trial was performed in infants who were not breast fed after the 14th day of birth. One hundred thirty-eight infants were enrolled and assigned to receive the control or experimental formula until they were 112 d old. Mean weight gain (primary outcome) and recumbent length, head circumference, tolerability (gastrointestinal symptoms), and overall morbidity (secondary outcomes) were measured at 14, 28, 56, 84, and 112 d of age.

Results: Equivalence in mean weight gain between the two groups was shown. The treatment difference in the intention-to-treat and per-protocol populations were within the predefined equivalence boundaries of +/-3.9 g/d. No statistically significant difference in recumbent length, head circumference, or incidence of adverse events was found between the two groups. Infants in the experimental group had fewer incidences of constipation and had stool characteristics that suggest that the experimental formula was tolerated well. Furthermore, these infants showed a trend toward fewer respiratory tract infections.

Conclusions: The starter formula containing BL999 and galacto-oligosaccharides/fructo-oligosaccharides is safe and well-tolerated.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Bifidobacterium longum B1-05Improved Stool CharacteristicsBeneficial
Small
Bifidobacterium longum B1-05Improved Weight GainNeutral
Small
Bifidobacterium longum B1-05Reduced ConstipationBeneficial
Moderate
Bifidobacterium longum B1-05Reduced Respiratory Tract InfectionsBeneficial
Small
Bifidobacterium longum B1-05Similar Growth MetricsNeutral
Small
Bifidobacterium longum BI-05Equivalence in Weight GainNeutral
Small
Bifidobacterium longum BI-05No Difference in Recumbent LengthNeutral
Moderate
Bifidobacterium longum BI-05Reduced Incidence of ConstipationBeneficial
Moderate
Bifidobacterium longum BL03Improved Growth Metrics StabilityNeutral
Moderate
Bifidobacterium longum BL03Increased Body WeightNeutral
Moderate
Bifidobacterium longum BL03Reduced ConstipationBeneficial
Moderate
Bifidobacterium longum BL03Reduced Respiratory Tract InfectionsBeneficial
Small
Bifidobacterium longum HA-135Increased Body WeightNeutral
Moderate
Bifidobacterium longum HA-135Reduced ConstipationBeneficial
Moderate
Bifidobacterium longum HA-135Reduced Respiratory Tract InfectionsBeneficial
Small
Bifidobacterium longum iVE-15Improved Stool CharacteristicsBeneficial
Small
Bifidobacterium longum MAK34B12LIncreased WeightNeutral
Moderate
Bifidobacterium longum MAK34B12LReduced ConstipationBeneficial
Moderate
Bifidobacterium longum MAK34B12LReduced Respiratory Tract InfectionsBeneficial
Small
Bifidobacterium longum MM-2Increased Weight GainNeutral
Moderate
Bifidobacterium longum MM-2Reduced ConstipationBeneficial
Moderate
Bifidobacterium longum MM-2Reduced Respiratory Tract InfectionsBeneficial
Small
Bifidobacterium longum Rosell-175Improved Stool CharacteristicsBeneficial
Small
Bifidobacterium longum Rosell-175Increased Body WeightNeutral
Moderate
Bifidobacterium longum Rosell-175No Change in Head CircumferenceNeutral
Small
Bifidobacterium longum Rosell-175No Difference in Recumbent LengthNeutral
Moderate
Bifidobacterium longum Rosell-175Reduced Incidence of Adverse EventsNeutral
Small
Bifidobacterium longum Rosell-175 MEImproved TolerabilityBeneficial
Moderate
Bifidobacterium longum Rosell-175 MEIncreased Body WeightNeutral
Moderate
Bifidobacterium longum Rosell-175 MEReduced ConstipationBeneficial
Moderate
Bifidobacterium longum Rosell-175 MEReduced Respiratory Tract InfectionsBeneficial
Small
Bifidobacterium longum SD-5588Achieved Normal Weight GainNeutral
Moderate
Bifidobacterium longum SD-5588Reduced Incidence of ConstipationBeneficial
Moderate
Bifidobacterium longum SD-5588Reduced Respiratory Tract InfectionsBeneficial
Small
Bifidobacterium longum SP54Increased Body WeightNeutral
Moderate
Bifidobacterium longum SP54No Change in Head CircumferenceNeutral
Small
Bifidobacterium longum SP54No Difference in Recumbent LengthNeutral
Moderate
Bifidobacterium longum SP54Reduced ConstipationBeneficial
Moderate
Bifidobacterium longum SP54Reduced Incidence of Adverse EventsNeutral
Small
Bifidobacterium longum SP54Reduced Respiratory InfectionsBeneficial
Small
Bifidobacterium longum subsp. longum UABI-14Equivalence in Growth ParametersNeutral
Moderate
Bifidobacterium longum subsp. longum UABI-14Reduced ConstipationBeneficial
Moderate
Bifidobacterium longum subsp. longum UABI-14Reduced Respiratory Tract InfectionsBeneficial
Small
Bifidobacterium longum UABI-14Equivalence in Weight GainNeutral
Small
Bifidobacterium longum UABI-14Reduced ConstipationBeneficial
Moderate
Bifidobacterium longum UABl-14Increased Body WeightNeutral
Moderate
Bifidobacterium longum UABl-14Increased General MorbidityNeutral
Small
Bifidobacterium longum UABl-14Reduced ConstipationBeneficial
Moderate
Bifidobacterium longum UABl-14Reduced Respiratory InfectionsBeneficial
Small
⬆ Back to top
Unsubscribe anytime. See our Privacy Policy.
Pillser
Supplement Research and Comparison Website: evidence-based information about supplements, their benefits, potential risks, and their efficacy.

Join Our Community

Statements on this website have not been reviewed by the U.S. Food and Drug Administration. These products are not meant to diagnose, treat, cure, or prevent any disease. The information here is not a replacement for personal medical advice.